Literature DB >> 11122852

Fenretinide and cancer prevention.

R Torrisi1, A Decensi.   

Abstract

A characteristic feature of fenretinide is the ability to inhibit cell growth through the induction of apoptosis with mechanisms that may be both receptor-dependent and receptor-independent. Chemopreventive efficacy of fenretinide has been investigated in clinical trials targeted at different organs. Results of a phase III secondary prevention trial suggest a benefit in preventing second breast malignancies in premenopausal women with early breast cancer. A potential benefit of fenretinide with ovarian cancer and a reduction of new occurrences of leukoplakia have also been observed in clinical trials with this agent. However, no effects on DNA content of urothelial cells from bladder washings and on recurrence rate were noted in a study of patients with superficial bladder tumors. Future trials using surrogate biomarkers may aid in rapid evaluation of the chemopreventive activity of fenretinide with various targeted organs.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11122852     DOI： 10.1007/s11912-000-0077-x

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  50 in total

1.  Assessment of DNA flow cytometry as a surrogate end point biomarker in a bladder cancer chemoprevention trial.

Authors:  S Bruno; R Torrisi; M Costantini; L Baglietto; V Fontana; B Gatteschi; G Melioli; G Nicolo; A Curotto; B Malcangi; G P Bruttini; M Varaldo; P Bruzzi; A Decensi
Journal:  J Cell Biochem       Date:  1999-12       Impact factor: 4.429

2.  Ocular effects of fenretinide, a vitamin A analog, in a chemoprevention trial of bladder cancer.

Authors:  L Baglietto; R Torrisi; G Arena; F Tosetti; A G Gonzaga; W Pasquetti; C Robertson; A Decensi
Journal:  Cancer Detect Prev       Date:  2000

3.  Induction of apoptosis by N-(4-hydroxyphenyl)retinamide and its association with reactive oxygen species, nuclear retinoic acid receptors, and apoptosis-related genes in human prostate carcinoma cells.

Authors:  S Y Sun; P Yue; R Lotan
Journal:  Mol Pharmacol       Date:  1999-03       Impact factor: 4.436

4.  Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms.

Authors:  S Y Sun; W Li; P Yue; S M Lippman; W K Hong; R Lotan
Journal:  Cancer Res       Date:  1999-05-15       Impact factor: 12.701

5.  Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point.

Authors:  A Decensi; R Torrisi; S Bruno; M Costantini; A Curotto; G Nicolò; B Malcangi; L Baglietto; G P Bruttini; B Gatteschi; G Rondanina; M Varaldo; M Perloff; W F Malone; P Bruzzi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-10       Impact factor: 4.254

6.  N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma.

Authors:  M S Sheikh; Z M Shao; X S Li; J V Ordonez; B A Conley; S Wu; M I Dawson; Q X Han; W R Chao; T Quick
Journal:  Carcinogenesis       Date:  1995-10       Impact factor: 4.944

7.  4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors.

Authors:  A N Fanjul; D Delia; M A Pierotti; D Rideout; J Q Yu; M Pfahl; J Qiu
Journal:  J Biol Chem       Date:  1996-09-13       Impact factor: 5.157

8.  Effects of fenretinide (4-HPR) on dark adaptation.

Authors:  R C Caruso; J Zujewski; F Iwata; M J Podgor; B A Conley; L M Ayres; M I Kaiser-Kupfer
Journal:  Arch Ophthalmol       Date:  1998-06

9.  Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients.

Authors:  F Formelli; R Carsana; A Costa; F Buranelli; T Campa; G Dossena; A Magni; M Pizzichetta
Journal:  Cancer Res       Date:  1989-11-01       Impact factor: 12.701

10.  Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase.

Authors:  S Kato; H Endoh; Y Masuhiro; T Kitamoto; S Uchiyama; H Sasaki; S Masushige; Y Gotoh; E Nishida; H Kawashima; D Metzger; P Chambon
Journal:  Science       Date:  1995-12-01       Impact factor: 47.728
View more
  3 in total

1.  A review of the nonsurgical treatment of oral leukoplakia.

Authors:  Adriana Spinola Ribeiro; Patrícia Ribeiro Salles; Tarcília Aparecida da Silva; Ricardo Alves Mesquita
Journal:  Int J Dent       Date:  2010-02-23

2.  Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth.

Authors:  J B Patel; J Mehta; A Belosay; G Sabnis; A Khandelwal; A M H Brodie; D R Soprano; V C O Njar
Journal:  Br J Cancer       Date:  2007-03-27       Impact factor: 7.640

3.  Combining a BCL2 inhibitor with the retinoid derivative fenretinide targets melanoma cells including melanoma initiating cells.

Authors:  Nabanita Mukherjee; Steven N Reuland; Yan Lu; Yuchun Luo; Karoline Lambert; Mayumi Fujita; William A Robinson; Steven E Robinson; David A Norris; Yiqun G Shellman
Journal:  J Invest Dermatol       Date:  2014-10-28       Impact factor: 8.551
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.